TABLE 2.

Patient Characteristics According to Prescribed Drug Class

Patient CharacteristicsNiflumic Acid, %Other NSAIDs, %Acetaminophen, %Other Analgesics, %Total, N
Gender
    Female47.548.148.248.138 256
    Male52.551.951.851.941 672
Age, y**
    0–357.020.665.762.540 695
    4–628.830.619.619.520 746
    7–99.627.99.610.711 375
    10–144.620.95.07.37116
Geographical area***
    North64.076.348.160.149 238
    Center23.014.920.223.416 446
    South13.08.931.716.514 248
Indications (mutually exclusive categories)***
    Otitis media9.97.49.94.57453
    Upper respiratory tract infection46.744.837.838.734 461
    Gastrointestinal infection0.5.83.92.31354
    Bronchitis/pneumonia1.61.12.41.81386
    Exanthematic disease0.20.21.90.8621
    Other infectious diseases5.47.015.29.37337
    Symptoms of no clear origin10.610.95.211.67199
    Trauma (including articular and genital problems)0.83.30.62.51163
    History of allergy0.20.20.20.3265
    Dermatological disease0.10.10.10.2109
    General check-up4.73.78.36.04418
    Other2.52.62.42.62233
    Not coded/unknown16.017.911.919.411 933
Use of NSAIDs during previous 30 d**
    None93.894.691.794.074 583
    1 drug5.95.17.65.65016
    ≥2 drugs0.30.30.70.4333
Concomitant drug use
    Antibiotics35.534.3*43.2*32.3*30 182
    Penicillins10.512.5*14.7*10.19930
    Amoxicillin6.55.510.47.26010
    Amoxicillin + clavulanic acid3.96.74.12.43753
Cephalosporins16.914.0*20.4*14.7*13 905
    Cefuroxime1.11.21.10.9870
    Cefaclor5.94.48.85.35244
    Cefixim3.93.94.54.93348
    Cefpodoxim0.60.40.50.2370
    Ceftibuten3.62.83.31.92579
    Cefprozil1.20.81.30.7864
    Sulfonamides0.20.4*0.7*0.5*338
    Macrolides8.68.47.9*7.86635
    Antimycotic agents0.20.20.4*0.2237
    Antimycobacterial agents0.00.10.10.043
    Antiviral agents0.40.40.8*0.2410
Total30 12119 40124 052382679 932
  • Comparison with niflumic acid category. P values are based on the χ2 test:

  • * P < .01;

  • P < .05.